pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
velaglucerase alfa
Phase 3 · mab · Gaucher Disease
velaglucerase alfa for Gaucher Disease is a Phase 3 program (mab) at Shire with 1 ClinicalTrials.gov record(s).
Internal code HGT-GCB-087
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Phase 3
- Modality
- mab
- Indication
- Gaucher Disease
- Status
- completed
- Trials
- 1